Edgewise Therapeutics Financial Statements
NASDAQ: EWTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
39.06-0.17 (-0.43%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edgewise Therapeutics revenue and earnings
Edgewise Therapeutics reported a net loss of $167.8 million, compared with a loss of $133.8 million a year earlier. Diluted earnings per share came in at -$1.63.
Summary generated from market data by MetaCap's automated system. Methodology
Edgewise Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 191.41M | 158.83M | 114.36M | 71.66M | 43.22M | 17.19M |
| Research & Development | 151.39M | 126.97M | 90.91M | 54.03M | 32.19M | 14.98M |
| Operating Income | -191.41M | -158.83M | -114.36M | -71.66M | -43.22M | -17.19M |
| Other Income (Expense) | 23.61M | 25.02M | 14.19M | 4.02M | 402.00K | 69.00K |
| Pretax Income | -167.80M | -133.80M | -100.20M | — | — | — |
| Income Tax | 4.00K | 3.00K | 4.00K | 0 | 0 | — |
| Net Income | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M | -17.12M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 | -23.17 |
| EPS (Diluted) | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 | -23.17 |
| Shares Outstanding (Basic) | 102.93M | 92.41M | 63.72M | 53.59M | 37.53M | 739.00K |
| Shares Outstanding (Diluted) | 102.93M | 92.41M | 63.72M | 53.59M | 37.53M | 739.00K |
| EBITDA | -189.32M | -156.76M | -112.81M | -71.29M | -42.94M | -17.01M |
This table shows 6 annual periods of Edgewise Therapeutics's income statement, from FY 2025 back to FY 2020, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow EWTX's reporting calendar. What is a income statement?